PN 400
As of the edition of 20 October 2026, PN 400 is a drug known only by a code name: went quiet in 2010; acts on ATP4A, ATP4B and PTGS1 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2010
- Kind
- Code name only
- Registered trials
- 9, 0 stopped early
- Disease areas
- Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 5 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of PN 400.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product5 company-target rows are on route A because of PN 400.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 9 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pozen | Lead sponsor of trials | 2008 to now |
| AstraZeneca | Lead sponsor of trials | 2008 to now |